Aptinyx Cashes In Post-Naurex Cache With $65 Million Series A
This article was originally published in Start Up
Executive Summary
Aptinyx, a biotechnology firm developing small molecules that modulate the NMDA receptor to treat neurological disorders, closed a $65 million Series A round, capitalizing on the cache that its management team gained from the sale of Naurex to Allergan.